Hematolojik Neoplazilerde Pegile-İnterferon Kullanımı
Özet
Interferon (IFN-α) is frequently used in various hematologic neoplastic and IFN-α has shown significant activity in treatment, but the therapy is handicapped by high dropout rates due to side effects and cumbersome dosing schedules. Pegylated (peg) IFN- α has longer serum half-life and acceptable toxicity, tolerability and activity profiles.
In this study, the use of PEG-IFN-α in different hematologic neoplasms, duration of response to treatment and toxicity were investigated. The data of 12 patients with polycythemia vera, 6 essential thrombocytosis, 2 CML, 1 primer myelofibrosis, 3 systemic mastocytosis, 1 hypereosinophilic syndrome, 4 Erdheim-Chester disease (ECD), 1 lymphomatoid granulomatosis patient were obtained from patient files and hospital electronic registration system using PEG-IFN-α.
The reason for the transition to PEG-IFN-α in 12 of 30 (40%) patients was resistance to previous treatments, and 10 (33.3%) had toxicity with previous treatments. In 8 patients (26.7%), PEG-IFN-α was given as the first-line treatment. Complete response was obtained in 41.6% of PV patients, partial response was obtained in 50% of patients, complete response was observed in 83.3% of ET patients, and 16.7% of patients were unresponsive. In 4 patients with systemic mastocytosis, PEG-IFN-α was initiated and clinical improvement was seen as the first-line treatment. In 4 patients with ECD, control images of PET showed stable disease in two patients, one patient had partial response and one patient had no response. Partial response was seen in patients with hypereosinophilic syndrome and lymphomatoid granulomatosis. In total, 8 out of 30 patients (26.6%) were found to have toxicity and 6 (20%) had to be discontinued due to toxicity.
As a result, despite the fact that PEG-IFN-α is an effective drug and its half-life has been prolonged, discontinuation rates due to toxicity are similar to the rates reported by the standard IFN-α in the literature.
